Samia Ammar Aldwaik

Dr. Samia Ammar Aldwaik

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2026 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
AAAmeer Awashra
Ameer Awashra
MAMohammed AbuBaha
Mohammed AbuBaha
BMBayan Mahafdah
Bayan Mahafdah
BABara AbuBaha
Bara AbuBaha
SASamia Ammar Aldwaik
Samia Ammar Aldwaik
ASAbdalhakim R. M. Shubietah
Abdalhakim R. M. Shubietah

8 July 2024 in Molecules
Verified
Journal Article
Open access
Mohammad QneibiMohammad Qneibi
Mohammad Qneibi
MHmohammed hawash
mohammed hawash
Sosana BdirSosana Bdir
Sosana Bdir
Mohammad BdairMohammad Bdair
Mohammad Bdair
SASamia Ammar Aldwaik
Samia Ammar Aldwaik
An optimal balance between excitatory and inhibitory transmission in the central nervous system provides essential neurotransmission for good functioning of the neurons. In the neurology field, a disturbed balance can lead to neurological diseases like epilepsy, Alzheimer’s, and Autism. One of the critical agents mediating excitatory neurotransmission is α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, which are concerned with synaptic plasticity, memory, and learning. An imbalance in neurotransmission finally results in excitotoxicity and neurological pathologies that should be corrected through specific compounds. Hence, the current study will prove to be an evaluation of new thiazole-carboxamide derivatives concerning AMPAR-modulating activity and extended medicinal potential. In the current project, five previously synthesized thiazole-carboxamide derivatives, i.e., TC-1 to TC-5, were used to interact with the AMPARs expressed in HEK293T cells, which overexpress different subunits of the AMPAR. Patch-clamp analysis was carried out while the effect of the drugs on AMPAR-mediated currents was followed with a particular emphasis on the kinetics of inhibition, desensitization, and deactivation. All tested TC compounds, at all subunits, showed potent inhibition of AMPAR-mediated currents, with TC-2 being the most powerful for all subunits. These compounds shifted the receptor kinetics efficiently, mainly enhancing the deactivation rates, and hence acted as a surrogate for their neuroprotective potentials. Additionally, recently published structure–activity relationship studies identified particular substituent groups as necessary for improving the pharmacologic profiles of these compounds. In this regard, thiazole-carboxamide derivatives, particularly those classified as TC-2, have become essential negative allosteric modulators of AMPAR function and potential therapeutics in neurological disturbances underlain by the dysregulation of excitatory neurotransmission. Given their therapeutic effectiveness and safety profiles, these in vivo studies need to be further validated, although computational modeling can be further developed for drug design and selectivity. This will open possibilities for new drug-like AMPAR negative allosteric modulators with applications at the clinical level toward neurology.

23 September 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
IRIslam Rajab
Islam Rajab
MMMonica Pernia Marin
Monica Pernia Marin
ASAbdalhakim R. M. Shubietah
Abdalhakim R. M. Shubietah
AKAyman Khaled
Ayman Khaled
Mohammad BdairMohammad Bdair
Mohammad Bdair
MSMary M. Salvatore
Mary M. Salvatore
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder caused by mutations in the SERPINA1 gene, resulting in reduced or dysfunctional alpha-1 antitrypsin (AAT) protein. This deficiency leads to progressive lung and liver diseases, including emphysema, chronic obstructive pulmonary disease, and cirrhosis. Despite its clinical significance, AATD remains underdiagnosed, delaying treatment. This review explores the molecular mechanisms of AATD, emphasizing Z-variant AAT protein accumulation in hepatocytes and excessive protease activity in the lungs. Advancements in imaging modalities – such as computed tomography, magnetic resonance imaging (MRI), dark-field radiography, and hyperpolarized MRI – enhance early diagnosis and disease monitoring. Novel therapies are reshaping AATD management, including small interfering RNA therapies (fazirsiran, belcesiran), gene-editing techniques (CRISPR-Cas9), regenerative approaches, autophagy-enhancing drugs, proteostasis regulators, aerosolized AAT, and artificial intelligence (AI) for real-time disease tracking via wearable devices. The integration of AI, advanced imaging, and emerging therapies represents a paradigm shift in AATD diagnosis and treatment. This review highlights the need for a multidisciplinary approach, early intervention, and personalized medicine to improve outcomes in both pulmonary and hepatic complications.

29 November 2025 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
MAMohammed AbuBaha
Mohammed AbuBaha
SASamia Ammar Aldwaik
Samia Ammar Aldwaik
BABara Abubaha
Bara Abubaha
AZAnwar Zahran
Anwar Zahran
DSDana Sandouka
Dana Sandouka
NSNadeen Sandoqah
Nadeen Sandoqah
Asthma is a common chronic inflammatory disease in children. Pediatric asthma has a wide range of immunologic phenotypes and different treatment responses. Recent data from various studies suggest that the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, a cytosolic multiprotein complex, has a central role in innate immunity, may be implicated in pediatric asthma pathogenesis, especially in the neutrophilic corticosteroid-resistant type. This review article investigates the mechanism of NLRP3 inflammasome activation as well as its role in airway inflammation and its expression in pediatric asthma based on sputum studies. The findings emphasize an association between elevated NLRP3 levels and poor asthma control. The need for novel treatments is important because Current using therapies such as corticosteroids and biologics demonstrate variable efficacy. According to data, their efficacy heavily depends on the underlying inflammatory phenotype. Biologics such as mepolizumab, benralizumab, and dupilumab are well known for their corticosteroid-sparing effects especially in cases of severe eosinophilic asthma. even though, their therapeutic benefits are limited when it comes to neutrophilic or steroid-resistant phenotypes. NLRP3 inhibitors are new, promising treatments which emerged recently and show potential capability in reducing airway inflammation in animal models. Furthermore, NLRP3-driven inflammation appears to play a role not only in asthma but also in inflammatory bowel disease and juvenile idiopathic arthritis, indicating a wider relevance for therapies that target the inflammasome pathway. Although promising data, application of this data in clinical practice is still challenging due to many causes, including diagnostic challenges, ethical considerations in trials involving children, and the lack of approved NLRP3 inhibitors for use in children. More research is required and essential to confirm that NLRP3 could be used as a biomarker or therapeutic target in pediatric asthma. Graphical abstract

24 January 2026 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
MAMohammed AbuBaha
Mohammed AbuBaha
SASamia Ammar Aldwaik
Samia Ammar Aldwaik
AAAmeer Awashra
Ameer Awashra
FMFathi Milhem
Fathi Milhem
AZAnwar K Zahran
Anwar K Zahran
ASAbdalhakim Shubietah
Abdalhakim Shubietah
Severe burn injuries result in a massive systemic inflammatory and hypermetabolic response, often disrupting multiple organ systems, including the cardiovascular system. Cardiac troponins are frequently elevated in burn patients, but the interpretation of these elevations is hardly straightforward. Sometimes, elevated troponin means type 1 myocardial infarction (MI) due to an acute coronary event, but it might also reflect type 2 MI due to an imbalance between body oxygen demand and supply, or even non-ischemic myocardial injury from things like overwhelming inflammation, sepsis, or direct thermal effects on the heart itself. This narrative review explores the prevalence, underlying pathophysiological mechanisms, diagnostic challenges, and prognostic implications of troponin elevation in burn patients. We discussed the limitations of applying conventional MI diagnostic criteria in this unique population. The role of electrocardiographic and echocardiographic assessment, as well as the potential utility of high-sensitivity troponin assays, is also discussed. Understanding of how burn pathophysiology relates to myocardial injury is essential for accurate diagnosis, improved management, and better outcomes in this highly vulnerable group of patients.

7 April 2026 in Clinical Cardiology
Verified
Journal Article
Open access
BABara AbuBaha
Bara AbuBaha
SASamia Ammar Aldwaik
Samia Ammar Aldwaik
SSSarah Saife
Sarah Saife
YMYousef Mahmoud‐Barqawi
Yousef Mahmoud‐Barqawi
LOLayan Omar
Layan Omar
MAMohammed AbuBaha
Mohammed AbuBaha
Introduction: Cardiac arrhythmias remain a leading cause of cardiovascular morbidity and mortality worldwide, and conventional diagnostic tools such as electrocardiography and Holter monitoring may fail to detect transient or asymptomatic events. Recent advances in artificial intelligence (AI) and machine learning have enhanced arrhythmia detection, risk stratification, and treatment planning; however, most existing models rely primarily on statistical associations rather than underlying physiological mechanisms. Methods: This narrative review was conducted through a structured but non‐systematic literature search of PubMed, Scopus, and Google Scholar, covering studies published between 2000 and 2025. Search terms included combinations of “cardiac arrhythmia,” “atrial fibrillation,” “causal inference,” “structural causal models,” “digital twins,” “mechanistic modeling,” “cardiac electrophysiology modeling,” and “artificial intelligence.” Peer‐reviewed articles were included if they demonstrated methodological depth and addressed causal inference or mechanistic modeling approaches in cardiovascular research, particularly in arrhythmia detection, risk prediction, treatment optimization, or clinical validation frameworks. Studies were prioritized based on methodological rigor, translational relevance, and recency. Editorials lacking methodological detail, non‐English publications, and studies relying solely on predictive models without incorporating causal or mechanistic components were excluded. Results: Causal artificial intelligence (Causal AI), offers a more mechanistically grounded framework for understanding arrhythmogenesis and therapeutic outcomes. Emerging evidence suggests that integrating clinical data with structural causal models, mechanistic modeling, and patient‐specific digital twins can bridge the gap between predictive performance and physiological interpretability. These approaches show promise in predicting ablation success, guiding therapy, and improving individualized care. Conclusion: Despite this potential, clinical implementation remains limited due to data heterogeneity, validation challenges, and regulatory constraints.